These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
267 related articles for article (PubMed ID: 30273935)
1. The 3PAs: An Update on the Association of Pheochromocytomas, Paragangliomas, and Pituitary Tumors. Xekouki P; Brennand A; Whitelaw B; Pacak K; Stratakis CA Horm Metab Res; 2019 Jul; 51(7):419-436. PubMed ID: 30273935 [TBL] [Abstract][Full Text] [Related]
2. Pituitary adenoma with paraganglioma/pheochromocytoma (3PAs) and succinate dehydrogenase defects in humans and mice. Xekouki P; Szarek E; Bullova P; Giubellino A; Quezado M; Mastroyannis SA; Mastorakos P; Wassif CA; Raygada M; Rentia N; Dye L; Cougnoux A; Koziol D; Sierra Mde L; Lyssikatos C; Belyavskaya E; Malchoff C; Moline J; Eng C; Maher LJ; Pacak K; Lodish M; Stratakis CA J Clin Endocrinol Metab; 2015 May; 100(5):E710-9. PubMed ID: 25695889 [TBL] [Abstract][Full Text] [Related]
3. Clinical significance and peculiarities of succinate dehydrogenase B and hypoxia inducible factor 1α expression in parasympathetic versus sympathetic paragangliomas. Bernardo-Castiñeira C; Sáenz-de-Santa-María I; Valdés N; Astudillo A; Balbín M; Pitiot AS; Jiménez-Fonseca P; Scola B; Tena I; Molina-Garrido MJ; Sevilla MA; Beristein E; Forga L; Villabona C; Oriola J; Halperin I; Suarez C; Chiara MD Head Neck; 2019 Jan; 41(1):79-91. PubMed ID: 30549360 [TBL] [Abstract][Full Text] [Related]
4. Non-pheochromocytoma (PCC)/paraganglioma (PGL) tumors in patients with succinate dehydrogenase-related PCC-PGL syndromes: a clinicopathological and molecular analysis. Papathomas TG; Gaal J; Corssmit EP; Oudijk L; Korpershoek E; Heimdal K; Bayley JP; Morreau H; van Dooren M; Papaspyrou K; Schreiner T; Hansen T; Andresen PA; Restuccia DF; van Kessel I; van Leenders GJ; Kros JM; Looijenga LH; Hofland LJ; Mann W; van Nederveen FH; Mete O; Asa SL; de Krijger RR; Dinjens WN Eur J Endocrinol; 2014 Jan; 170(1):1-12. PubMed ID: 24096523 [TBL] [Abstract][Full Text] [Related]
5. 15 YEARS OF PARAGANGLIOMA: The association of pituitary adenomas and phaeochromocytomas or paragangliomas. O'Toole SM; Dénes J; Robledo M; Stratakis CA; Korbonits M Endocr Relat Cancer; 2015 Aug; 22(4):T105-22. PubMed ID: 26113600 [TBL] [Abstract][Full Text] [Related]
6. Germinal defects of SDHx genes in patients with isolated pituitary adenoma. Mougel G; Lagarde A; Albarel F; Essamet W; Luigi P; Mouly C; Vialon M; Cuny T; Castinetti F; Saveanu A; Brue T; Barlier A; Romanet P Eur J Endocrinol; 2020 Oct; 183(4):369-379. PubMed ID: 32621582 [TBL] [Abstract][Full Text] [Related]
7. SDHD immunohistochemistry: a new tool to validate SDHx mutations in pheochromocytoma/paraganglioma. Menara M; Oudijk L; Badoual C; Bertherat J; Lepoutre-Lussey C; Amar L; Iturrioz X; Sibony M; Zinzindohoué F; de Krijger R; Gimenez-Roqueplo AP; Favier J J Clin Endocrinol Metab; 2015 Feb; 100(2):E287-91. PubMed ID: 25405498 [TBL] [Abstract][Full Text] [Related]
8. 3P association (3PAs): Pituitary adenoma and pheochromocytoma/paraganglioma. A heterogeneous clinical syndrome associated with different gene mutations. Guerrero-Pérez F; Fajardo C; Torres Vela E; Giménez-Palop O; Lisbona Gil A; Martín T; González N; Díez JJ; Iglesias P; Robledo M; Villabona C Eur J Intern Med; 2019 Nov; 69():14-19. PubMed ID: 31431315 [TBL] [Abstract][Full Text] [Related]
9. Heterogeneous genetic background of the association of pheochromocytoma/paraganglioma and pituitary adenoma: results from a large patient cohort. Dénes J; Swords F; Rattenberry E; Stals K; Owens M; Cranston T; Xekouki P; Moran L; Kumar A; Wassif C; Fersht N; Baldeweg SE; Morris D; Lightman S; Agha A; Rees A; Grieve J; Powell M; Boguszewski CL; Dutta P; Thakker RV; Srirangalingam U; Thompson CJ; Druce M; Higham C; Davis J; Eeles R; Stevenson M; O'Sullivan B; Taniere P; Skordilis K; Gabrovska P; Barlier A; Webb SM; Aulinas A; Drake WM; Bevan JS; Preda C; Dalantaeva N; Ribeiro-Oliveira A; Garcia IT; Yordanova G; Iotova V; Evanson J; Grossman AB; Trouillas J; Ellard S; Stratakis CA; Maher ER; Roncaroli F; Korbonits M J Clin Endocrinol Metab; 2015 Mar; 100(3):E531-41. PubMed ID: 25494863 [TBL] [Abstract][Full Text] [Related]
10. Succinate dehydrogenase (SDHx) mutations in pituitary tumors: could this be a new role for mitochondrial complex II and/or Krebs cycle defects? Xekouki P; Stratakis CA Endocr Relat Cancer; 2012 Dec; 19(6):C33-40. PubMed ID: 22889736 [TBL] [Abstract][Full Text] [Related]
11. Succinate dehydrogenase (SDH) D subunit (SDHD) inactivation in a growth-hormone-producing pituitary tumor: a new association for SDH? Xekouki P; Pacak K; Almeida M; Wassif CA; Rustin P; Nesterova M; de la Luz Sierra M; Matro J; Ball E; Azevedo M; Horvath A; Lyssikatos C; Quezado M; Patronas N; Ferrando B; Pasini B; Lytras A; Tolis G; Stratakis CA J Clin Endocrinol Metab; 2012 Mar; 97(3):E357-66. PubMed ID: 22170724 [TBL] [Abstract][Full Text] [Related]
12. SDHx mutation and pituitary adenoma: can in vivo 1H-MR spectroscopy unravel the link? Branzoli F; Salgues B; Marjańska M; Laloi-Michelin M; Herman P; Le Collen L; Delemer B; Riancho J; Kuhn E; Jublanc C; Burnichon N; Amar L; Favier J; Gimenez-Roqueplo AP; Buffet A; Lussey-Lepoutre C Endocr Relat Cancer; 2023 Feb; 30(2):. PubMed ID: 36449569 [TBL] [Abstract][Full Text] [Related]